Impact of abnormal metabolic-immunoinflammatory pathway on splenomegaly in patients with chronic schizophrenia and exploration of risk factors: case-control study - Report - MDSpire
Advertisement
Impact of abnormal metabolic-immunoinflammatory pathway on splenomegaly in patients with chronic schizophrenia and exploration of risk factors: case-control study
Risk Factors and Metabolic-Inflammatory Links to Splenomegaly in Chronic Schizophrenia
Overview
This case-control study of 426 chronic schizophrenia patients identified metabolic abnormalities, immunoinflammatory activation, and prominent negative symptoms as key factors associated with splenomegaly. Use of aripiprazole was independently linked to reduced odds of splenomegaly, suggesting a protective effect.
Background
Chronic schizophrenia is associated with increased somatic comorbidities including metabolic syndrome, liver injury, and immune dysfunction. These complications are often under-recognized due to impaired symptom perception and reporting. The spleen, a central immune and metabolic organ, may be affected by dysregulated metabolic-immunoinflammatory pathways in schizophrenia, but its role has been understudied. Understanding splenomegaly and its risk factors could improve somatic monitoring and intervention strategies in this population.
Data Highlights
Parameter
Splenomegaly Group (n=165)
Non-Splenomegaly Group (n=261)
Significance (p)
Lipoprotein(a)
Higher
Lower
<0.05
Cholesterol
Higher
Lower
<0.05
Triglycerides
Higher
Lower
<0.05
HbA1c
Higher
Lower
<0.05
C-reactive protein (CRP)
Higher
Lower
<0.05
Interleukin-6 (IL-6)
Higher
Lower
<0.05
β2-microglobulin
Higher
Lower
<0.05
Fatty liver incidence
Higher
Lower
<0.05
PANSS negative symptom score
Higher
Lower
<0.05
Aripiprazole use rate
Lower
Higher
<0.05
Key Findings
Splenomegaly in chronic schizophrenia patients is associated with elevated metabolic markers including lipoprotein(a), cholesterol, triglycerides, and HbA1c.
Inflammatory markers CRP, IL-6, and β2-microglobulin are significantly higher in patients with splenomegaly, indicating immunoinflammatory activation.
Patients with splenomegaly have a higher incidence of fatty liver and more severe negative psychiatric symptoms as measured by PANSS.
Binary logistic regression identified HbA1c and PANSS negative symptom score as independent risk factors for splenomegaly.
Use of aripiprazole is independently associated with reduced odds of splenomegaly, suggesting a protective metabolic and anti-inflammatory effect.
Clinical Implications
Clinicians should monitor metabolic and inflammatory parameters in chronic schizophrenia patients to identify those at risk for splenomegaly. Negative symptoms may serve as an early clinical indicator warranting further somatic evaluation. Considering aripiprazole as part of antipsychotic therapy may help reduce splenomegaly risk through its favorable metabolic and immunomodulatory profile.
Conclusion
Splenomegaly in chronic schizophrenia reflects underlying metabolic and immunoinflammatory dysregulation and correlates with negative symptom severity. Aripiprazole use appears to mitigate this risk, highlighting the importance of integrated psychiatric and somatic care.
References
Study Authors/2024 -- Influence of Dysregulated Metabolic-Immunoinflammatory Pathways on Splenomegaly in Chronic Schizophrenia Patients
Longitudinal cohort data linked bullying and persistently unsupportive state gender-identity policies with worsening psychotic-like experiences among gender-diverse youths.
